Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the pharmacokinetics and safety of Singulair (10 mg) and Xyzal (5 mg) in free combination and fixed-dose combination as HCP1102
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TR | Experimental | HCP1102(Singulair and Xyzal combination tablet) -> coadministration of Singulair and Xyzal |
|
| RT | Experimental | coadministration of Singulair and Xyzal -> HCP1102(Singulair and Xyzal combination tablet) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HCP1102 | Drug |
|
| |
| Singulair and Xyzal |
| Measure | Description | Time Frame |
|---|---|---|
| AUClast | 0-34hr | |
| Cmax | 0-34hr |
| Measure | Description | Time Frame |
|---|---|---|
| tmax | 0-34hr | |
| AUCinf | 0-34hr | |
| t1/2 | 0-34hr |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Samsung medical center | Seoul | South Korea |
Not provided
| ID | Term |
|---|---|
| D012220 | Rhinitis |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C093875 | montelukast |
| C472067 | levocetirizine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
|
| D010038 |
| Otorhinolaryngologic Diseases |